Characterization of antitumor auto-antibodies using combinatorial peptide librari

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$272,360.00
Award Year:
2012
Program:
SBIR
Phase:
Phase I
Contract:
1R43CA168014-01A1
Award Id:
n/a
Agency Tracking Number:
R43CA168014
Solicitation Year:
2012
Solicitation Topic Code:
NCI
Solicitation Number:
PA09-189
Small Business Information
11 DEER PARK DR, STE 104, MONMOUTH JUNCTION, NJ, -
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
27661870
Principal Investigator:
WLODEK MANDECKI
(732) 355-0100
mandecki@pharmaseq.com
Business Contact:
WLODEK MANDECKI
(732) 355-0100
mandecki@pharmaseq.com
Research Institution:
Stub




Abstract
DESCRIPTION (provided by applicant): The development of circulating auto-antibodies to tumor-associated antigens (TAAs) has been observed at early cancer stages. TAA auto-antibodies are attractive as diagnostic markers because they are stable and persistent in cancerous conditions yet minimally present in normal individuals and most noncancerous conditions. However, the identification of auto-antibodies specific for a particular type of cancer is complicated due to the relatively low-abundance of an individual antibody within the complexity of the human proteome. The purpose of the present project is to develop an approach to detect auto-antibodies to tumor-associated antigens using an encoded combinatorial peptide library synthesized on PharmaSeq's light-activated radio-frequency p-Chips. Preparing the combinatorial library on the p-Chip platform serves two purposes: 1) to enrich for low-abundance proteins based on established principles of solid-phase affinity adsorption and 2) to rapidly identify the affinity ligand on each chip based on the encoded ID. The main project goal is to synthesize an RFID-encoded peptide library consisting of several thousands of random tetramers using the split-and-mix method. We will use a high speed fluidics-based analytical instrument previously developed by PharmaSeq to identify p-Chips carrying specific peptides with affinity to human auto- antibodies. In addition we will quantitatively characterize differences in immunoglobulin profiles between early stage ovarian andbreast cancer patient and normal control samples. The methods developed will enable, for the first time, a true encoded one- particle-one-compound high throughput library synthesis and screening method that is capable of direct translation as a clinical diagnostic platform. PUBLIC HEALTH RELEVANCE: Auto-antibodies generated against tumor-associated antigens show great potential for the accurate, early diagnosis of cancer but identifying antibodies specific to a particular type of cancer is challenging, requiring a sensitive, high-throughput system that can discriminate key biomarkers against a high protein load. The implementation of an RFID- encoded combinatorial peptide library with PharmaSeq's light-activated p-Chip system will enable the simultaneous enrichment and identification of clinically-relevant biomarkers on a unified, high-throughput platform.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government